
ReproCELL Incorporated — Investor Relations & Filings
ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ | 2026-05-22 | Japanese | |
| 確認書 | 2025-11-13 | Japanese | |
| 半期報告書-第24期(2025/04/01-2026/03/31) | 2025-11-13 | Japanese | |
| 内部統制報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | |
| 確認書 | 2025-06-26 | Japanese | |
| 有価証券報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese |
Browse filings by year
12 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
1 filing
| |||||
| 46779402 | 連結子会社(REPROCELL USA Inc.)に対する補助金の交付決定に関するお知らせ | 2026-05-22 | Japanese | ||
|
2025
5 filings
| |||||
| 8284113 | 確認書 | 2025-11-13 | Japanese | ||
| 8284101 | 半期報告書-第24期(2025/04/01-2026/03/31) | 2025-11-13 | Japanese | ||
| 7246941 | 内部統制報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | ||
| 7246936 | 確認書 | 2025-06-26 | Japanese | ||
| 7246939 | 有価証券報告書-第23期(2024/04/01-2025/03/31) | 2025-06-26 | Japanese | ||
|
2024
9 filings
| |||||
| 7298959 | 確認書 | 2024-11-13 | Japanese | ||
| 7298954 | 半期報告書-第23期(2024/04/01-2025/03/31) | 2024-11-13 | Japanese | ||
| 7325542 | 臨時報告書 | 2024-06-26 | Japanese | ||
| 7328563 | 内部統制報告書-第22期(2023/04/01-2024/03/31) | 2024-06-25 | Japanese | ||
| 7328560 | 確認書 | 2024-06-25 | Japanese | ||
| 7328561 | 有価証券報告書-第22期(2023/04/01-2024/03/31) | 2024-06-25 | Japanese | ||
| 7336087 | 臨時報告書 | 2024-05-23 | Japanese | ||
| 7356961 | 確認書 | 2024-02-09 | Japanese | ||
| 7356958 | 四半期報告書-第22期第3四半期(2023/10/01-2023/12/31) | 2024-02-09 | Japanese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Cardiol Therapeutics Inc.
Clinical-stage company developing anti-inflammatory therapi…
|
CRDL | CA | Professional, scientific and te… |
|
CASSAVA SCIENCES INC
Clinical-stage biotech developing treatments for Central Ne…
|
SAVA | US | Professional, scientific and te… |
|
Celcuity Inc.
Clinical-stage biotech developing targeted therapies for mu…
|
CELC | US | Professional, scientific and te… |
|
Cell Bio Human Tech Co., Ltd
Develops and manufactures cellulose-based nonwoven fabrics …
|
318160 | KR | Professional, scientific and te… |
|
CEL SCI CORP
Clinical-stage biotech developing immunotherapies for cance…
|
CVM | US | Professional, scientific and te… |
|
Celyad Oncology SA
Biotechnology company developing innovative CAR-T cell ther…
|
CYAD | BE | Professional, scientific and te… |
|
Ceres Power Holdings PLC
A developer of solid oxide technology for clean power and g…
|
CWR | GB | Professional, scientific and te… |
|
Certara, Inc.
Accelerates drug development using biosimulation software, …
|
CERT | US | Professional, scientific and te… |
|
CervoMed Inc.
A clinical-stage biotech developing treatments for age-rela…
|
CRVO | US | Professional, scientific and te… |
|
Chabiotech Co.,Ltd.
Develops cell/gene therapies and provides CDMO and bio-bank…
|
085660 | KR | Professional, scientific and te… |
ReproCELL Incorporated via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/13724/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=13724 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=13724 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=13724 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 13724}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ReproCELL Incorporated (id: 13724)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.